-
公开(公告)号:US6136964A
公开(公告)日:2000-10-24
申请号:US618651
申请日:1996-03-19
CPC分类号: C12N9/1029
摘要: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
摘要翻译: 公开了具有酶溶血磷脂酸酰基转移酶(LPAAT)活性的cDNA序列和多肽。 LPAAT也称为1-酰基sn-甘油-3-磷酸酰基转移酶。
-
公开(公告)号:US6060263A
公开(公告)日:2000-05-09
申请号:US400742
申请日:1999-09-21
CPC分类号: C12N9/1029
摘要: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
-
3.
公开(公告)号:US20080176288A1
公开(公告)日:2008-07-24
申请号:US11928737
申请日:2007-10-30
申请人: David W. Leung , Philip A. Bergman , Alan Lofquist , Gregory E. Pietz , Christopher K. Tompkins , David W. Waggoner
发明人: David W. Leung , Philip A. Bergman , Alan Lofquist , Gregory E. Pietz , Christopher K. Tompkins , David W. Waggoner
CPC分类号: C07K7/06 , A61K47/645 , C07K7/08 , C07K14/001 , C07K2319/00
摘要: A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.
摘要翻译: 聚阴离子聚合物可以改善与其结合的药物的生物活性和水溶性。 本发明的方法提供可以容易地操作的重组生产的聚阴离子聚合物的单分散制剂,例如延长的。 活性部分可以化学或重组连接到聚阴离子聚合物以增加其生物半衰期和/或溶解度。 本发明还提供了将聚阴离子聚合物缀合物或融合蛋白递送至特定细胞类型或组织的方法。
-
公开(公告)号:US07135314B1
公开(公告)日:2006-11-14
申请号:US08842827
申请日:1997-04-17
CPC分类号: C12P13/001 , C12N9/16 , C12P7/6463 , C12P7/6481 , C12P13/02
摘要: This invention relates to a biotechnology invention concerning human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-α(1 and 2), PAP-β and PAP-γ and uses thereof.
摘要翻译: 本发明涉及涉及人类磷脂酸磷酸酶的生物技术发明。 更具体地说,本发明涉及人磷脂酸磷酸酶的三种变体,即PAP-α(1和2),PAP-β和PAP-γ及其用途。
-
公开(公告)号:US06274363B1
公开(公告)日:2001-08-14
申请号:US09107149
申请日:1998-06-30
IPC分类号: C12N920
CPC分类号: C12N9/20
摘要: Three new isoforms of phosphatidylcholine phospholipase D, hPLD2.1, hPLD2.2 and hPLD1.5, can be produced recombinantly and are useful for screening compounds, as drug candidates, for an ability to modify PCPLD activity.
摘要翻译: 可以重组产生三种新的磷脂酰胆碱磷脂酶D,hPLD2.1,hPLD2.2和hPLD1.5的同种型,可用于筛选化合物作为药物候选物,以改变PCPLD活性的能力。
-
公开(公告)号:US5859222A
公开(公告)日:1999-01-12
申请号:US768147
申请日:1996-12-17
CPC分类号: C12N9/20
摘要: Disclosed are human cDNA and polypeptides sequences having phosphatidylcholine phospholipase D (PCPLD).
摘要翻译: 公开了具有磷脂酰胆碱磷脂酶D(PCPLD)的人cDNA和多肽序列。
-
-
-
-
-